Thrombophilia and lipid profile in post-menopausal women using a new transdermal oestradiol patch

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 66, Issue 2, 1996, Pages 165-168

  Habiba, Marwan ^a   Andrea, Akkad ^a   Phipps, Beverley ^a   Al Azzawi, Farook ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Apoprotein; Lipoprotein; Menopause; Thrombophilia; Transdermal oestradiol

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; ESTRADIOL; FIBRINOGEN; GYNADERM; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEIN C; PROTEIN S; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOPHILIA; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0029945581     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-2115(96)02400-1     Document Type: Article

References (21)

1. OPCS. On the state of the public health. The annual report of the chief medical officer of the Department of Health for the year of 1991. London: HMSO, Department of Health.
2. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75 (6): 1102-1109.
3. Henderson BE, Ross RK, Paganini-Hill A, Mack TM. Estrogen use and cardivascular disease. Reprod Med 1985; 30: 814-820.
4. Stampfer MJ, Willett WC, Colditz GA et al. A prospective study of post-menopausal estrogen therapy and coronary heart disease. N Engl J Med 1985; 313: 1044-1049.
5. Ross RK, Paganini-Hill A, Mack TM et al. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. N Engl J Med 1981; 313: 1044-1049.
6. Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO. Apoproteins B and AI and coronary artery disease in humans. Arteriosclerosis 1984; 4: 79-83.
7. Bhatnagar D, Durrington PN. Does measurement of apolipoproteins add to the clinical diagnosis and management of dyslipidaemias? Curr Op Lipidol 1993; 4; 299-304.
8. Scanu AM. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. J Am Med Assoc 1992; 267 (24): 3326-3329.
9. Averna MR, Barbagallo CM, Ocello S et al. Lp(a) levels in patients undergoing aorto-coronary bypass surgery. Eur Heart J 1992; 13 (10): 1405-1409.
10. Hayden MR, Reidy M. Many roads lead to atheroma. Nat Med 1995; 1 (1): 22-23.
11. Chetkowski RJ, Meldrum DR, Steingold KA et al. Biologic effects of transdermal oestradiol. N Engl J Med 1986; 19: 314 (25): 1615-1620.
12. Stanczyk FZ, Shoupe D, Nunez V et al. A randomized comparison of non-oral estradiol delivery in postenopausal women. Am J Obstet Gynecol 1988; 159 (6): 1540-1546.
13. Walsh BW, Schiff I, Rosner B et al. Effects of post-menopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-1204.
14. Crook D, Cust MP, Gangar KF et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950-955.
15. Field CS, Ory SJ, Wahner HW et al. Preventive effects of transdermal 17 β-estradiol on osteoporotic changes after surgical menopause: a 2-year placebo-controlled trial. Am J Obstet Gynecol 1993; 168: 1141-1121.
16. Cagnacci A, Soldani R, Carriero PL et al. Effects of low doses of transdermal 17 β-estradiol on carbohydrate metabolism in post-menopausal women. J Clin Endocrinol Metab 1992; 74 (6): 1396-1400.
17. Lee AJ, Lowe GD, Smith WC, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993; 83 (4): 616-621.
18. Samsioe G. Lipid profiles in estrogen users. In: Sitruk-Ware R, Utian WU, editors. The menopause and hormonal replacement therapy, facts and controversies. New York: Marcel Dekker, 1991; 181-200.
19. Caine YG, Bauer KA, Barzegar S et al. Coagulation activation following estrogen administration to post-menopausal women. Thromb Haemost 1992; 68 (4): 392-395.
20. Devor M, Barrett-Connor E, Revall M et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-285.
21. Pabinger I, Schneider B, the GTH Study Group. Thrombotic risk of women with hereditary antithrombin III, protein C and protein S deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71 (5), 548-552.